Brain injection trial offers hope for halting Huntington's
NCT ID NCT05541627
Summary
This early-stage study is testing a one-time gene therapy called AB-1001, delivered directly into the brain, in a small group of adults with early Huntington's disease. The main goals are to see if the treatment is safe and to look for early signs that it might slow the disease. Researchers will monitor participants for five years after the procedure to track their health and brain changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut du Cerveau (ICM), Hôpital La Pitié Salpêtrière APHP
Paris, Île-de-France Region, 75013, France
Conditions
Explore the condition pages connected to this study.